GLP-1R agonists clinical trial design must be improved to ease concerns

Glucagon-like peptide-1 (GLP-1) receptor agonists, such as Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro, have garnered a lot of attention in the pharma industry and beyond.

Related Keywords

Costanza Alciati , ,Bio Developments ,Pipelines ,Emerging Markets ,Glp 1 ,Eli Lilly ,Novo Nordisk ,Obesity ,Clinical Trial ,